Literature DB >> 11161857

Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma.

M Hirai1, A Nakagawara, T Oosaki, Y Hayashi, M Hirono, T Yoshihara.   

Abstract

OBJECTIVE: We investigated the expression of two angiogenic vascular endothelial growth factors, VEGF-A/VEGF-1 and VEGF-C/VEGF-2, in 228 cases of uterine endometrial carcinomas from postmenopausal patients to evaluate the correlation with histopathologic features and clinical outcome.
METHODS: Immunohistochemistry was used to assess VEGF-A/VEGF-1 and VEGF-C/VEGF-2 expression in 228 primary surgically treated cases of postmenopausal endometrial carcinomas and the results were statistically analyzed in relation to vascular invasion, depth of invasion (myometrial vs serosal-parametrial invasion), lymphatic vessel invasion, lymph node metastasis, disease-free 5-year survival rate (DF5YR), and disease-free 10 year-survival rate (DF10YR).
RESULTS: The results of univariate analysis showed that VEGF-A/VEGF-1 and VEGF-C/VEGF-2 expression correlated with vascular invasion (P < 0.0001, P = 0.0006), depth of invasion (P = 0.0004, P = 0.043), lymphatic vessel invasion (P = 0.021, P < 0.0001), lymph node metastasis (P = 0.0017, P = 0.0008), DF5YR (P = 0.0081, P = 0.0002), and DF10YR (P = 0.0077, P = 0.0001). Multivariate analysis showed that lymph node metastasis (P = 0.0017, P = 0.0008), parametrial-serosal invasion (P < 0.0001, P < 0.0001), and VEGF-C/VEGF-2-positive status (P = 0.03, P = 0.01) were significant factors in DF5YR and DF10YR.
CONCLUSIONS: We conclude that VEGF-A/VEGF-1 and VEGF-C/VEGF-2 expression was predictive of these histopathologic features of endometrial carcinoma and clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161857     DOI: 10.1006/gyno.2000.6056

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  27 in total

Review 1.  Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment.

Authors:  A S Felix; J Weissfeld; R Edwards; F Linkov
Journal:  Eur J Gynaecol Oncol       Date:  2010       Impact factor: 0.196

Review 2.  Personalized therapy in endometrial cancer: challenges and opportunities.

Authors:  Shannon N Westin; Russell R Broaddus
Journal:  Cancer Biol Ther       Date:  2012-01-01       Impact factor: 4.742

3.  A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

Authors:  D Scott McMeekin; Michael W Sill; Doris Benbrook; Kathleen M Darcy; Deborah J Stearns-Kurosawa; Lynne Eaton; S Diane Yamada
Journal:  Gynecol Oncol       Date:  2007-02-15       Impact factor: 5.482

4.  Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.

Authors:  Michael Frumovitz; Anil K Sood
Journal:  Gynecol Oncol       Date:  2007-03       Impact factor: 5.482

Review 5.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

Review 6.  Promising novel therapies for the treatment of endometrial cancer.

Authors:  Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-11-10       Impact factor: 5.482

7.  Endometrial Tumour Microenvironment.

Authors:  Carlos Casas-Arozamena; Miguel Abal
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

8.  Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma.

Authors:  Sami K Saarelainen; Synnöve Staff; Nina Peltonen; Terho Lehtimäki; Jorma Isola; Paula M Kujala; Maarit H Vuento; Johanna U Mäenpää
Journal:  Tumour Biol       Date:  2014-01-14

9.  Importance of Serum Copper and Vascular Endothelial Growth Factor (VEGF-A) Levels in Postmenopausal Bleeding.

Authors:  Afshan Rafi; Ramakrishna Devaki; K Sabitha; Shruti Mohanty; Pragna Rao
Journal:  Indian J Clin Biochem       Date:  2012-07-28

10.  A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

Authors:  Robert L Coleman; Michael W Sill; Heather A Lankes; Amanda Nickles Fader; Neil J Finkler; James S Hoffman; Peter G Rose; Gregory P Sutton; Charles W Drescher; D Scott McMeekin; Wei Hu; Michael Deavers; Andrew K Godwin; R Katherine Alpaugh; Anil K Sood
Journal:  Gynecol Oncol       Date:  2012-08-23       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.